Use to detect the 2019 novel coronavirus (SARS-CoV-2).
Qualitative Nucleic Acid Amplification
Also acceptable: Oropharyngeal or Nasal swab.
Refer to the "COVID-19 Specimen Collection Guide" at https://www.aruplab.com/infectious-disease/coronavirus/testing
Nasopharyngeal swab: Place in viral transport media, Liquid Amies, or saline (minimum volume 1.2mL). Place each specimen in an individually sealed bag.
Oropharyngeal or nasal swab: Place in viral transport media, Liquid Amies, or saline (minimum volume 1.2mL). Or collect using the Aptima Multitest Swab Collection Kit. Place each specimen in an individually sealed bag.
Also acceptable: Media that is equivalent to viral transport media or universal transport media.
Wood swabs, calcium alginate swabs.
Specimen source required.
Ambient: Unacceptable; Refrigerated: 2 days; Frozen: 1 month
This test should be ordered for the detection of the 2019 novel coronavirus SARS-CoV-2 in individuals who meet SARS-CoV-2 clinical and/or epidemiological criteria.
The Coronavirus SARS-CoV-2 (COVID-19) by nucleic acid amplification test is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA) for US laboratories certified under CLIA to perform high complexity tests. This test has not been FDA cleared or approved. In compliance with this authorization, please visit https://www.aruplab.com/infectious-disease/coronavirus for more information and to access the applicable information sheets.
If the result is Not Detected, this does not rule out the presence of PCR inhibitors in the patient specimen or assay specific nucleic acid in concentrations below the level of detection by the assay.
No compliance statements are in use for this test.
U0003; (Alt code: 87635)
|Component Test Code*||Component Chart Name||LOINC|
|3002640||SARS-CoV-2 by NAA||94500-6|
- Coronavirus disease - 2019
- COVID-19 Illness